Liquid Biopsy Under PSMA Radioligand Therapy
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic castration-resistant prostate cancer (mCRPC) can be offered radioligand therapy (RLT) that targets t
| Condition(s) | Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic castration-resistant prostate cancer (mCRPC) can be offered radioligand therapy (RLT) that targets the prostate-specific membrane antigen (PSMA). Despite an initially high response rate to PSMA-RLT, the disease often progresses rapidly again. The underlying mechanisms are still poorly understood. Liquid biopsy (LBx) involves the collection and analysis of body fluids, particularly blood. Its major advantage compared to a tissue sample is its non-invasive nature, allowing for multiple samplings, as well as the examination of more than just a single punctured lesion. Among ot |
| Who can participate | Inclusion Criteria: * Patients with mCRPC eligble for PSMA RLT * In-lable use for PSMA RLT * PSMA PET/CT not older than 8 weeks prior to first cycle of PSMA RLT * One previous line of antiandrogen receptor pathway treatment and one previous line of taxan based therapy * Age ≥ 18 years * Written informed consent * Sufficient knowledge of the German language or presence of a translator Exclusion Criteria: * Unwilling to adhere to study procedures * Missing interdisciplinary tumor conference advise for PSMA RLT |
| Sex | Male |
| Lead sponsor | Wuerzburg University Hospital |
| Locations | Augsburg, Germany; München, Germany; Würzburg, Germany |
| Start date | 2024-09-01 |
| NCT ID | NCT07118436 |
| Official listing | https://clinicaltrials.gov/study/NCT07118436 |